Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00640419 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

DRUG: ABT-089
DRUG: placebo

Sponsor

AbbVie (prior sponsor, Abbott)